Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 33)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
2 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
3 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
4 |
|
Metronidazole |
Approved |
Phase 2, Phase 3 |
|
443-48-1, 69198-10-3 |
4173 |
Synonyms:
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(Î’-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(Î’-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(Î’-oxyethyl)-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitroimidazole-1-ethanol
ACEA
Acromona
ANABACT
Anagiardil
Apo-Metronidazole
Arilin
Atrivyl
BAY-5360
Bayer 5360
BAYER-5360
Bexon
Clont
Cont
Danizol
Deflamon
Deflamon-Wirkstoff
DRAZIFON
Efloran
ELYZOL
Entizol
Eumin
Flagemona
Flagesol
Flagil
Flagyl
FLAGYL 375
FLAGYL COMPAK
FLAGYL ER
Flagyl I.V.
FLAGYL I.V. RTU IN PLASTIC CONTAINER
FLAGYL-400
FLAGYL-S
Flegyl
Fossyol
Giatricol
Gineflavir
Hydrochloride, metronidazole
Klion
Klont
Meronidal
Methronidazole
Metric
METRIC 21
Metro Cream
Metro I.V.
Metro I.V. In Plastic Container
METRO IV
METROCREAM
Metrodzhil
MetroGel
Metrogel-vaginal
Metrogyl
Metrolag
METROLOTION
METROLYL
|
METROMIDOL
Metronidaz
Metronidazol
METRONIDAZOLE
Métronidazole
Metronidazole benzoate
Metronidazole Hcl
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazolo
Metronidazolum
METROSA
METROTOP
Mexibol
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
Neo-Tric
NEUTRATOP
Nida
Nidagel
Noritate
Noritic acid
NORZOL
Novonidazol
NSC-50364
NSC-69587
NUVESSA
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
PROTOSTAT
Rathimed
ROSICED
ROZEX
RP-8823
Sanatrichom
Satric
Takimetol
Trichazol
Trichex
Tricho Cordes
Trichocide
Tricho-Gynaedron
Trichomol
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
Vagilen
Vagimid
VAGINYL
VANDAZOLE
Vertisal
Wagitran
ZADSTAT
ZIDOVAL
ZYOMET
|
|
5 |
|
Gemcitabine |
Approved |
Phase 3 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
6 |
|
Albumin-Bound Paclitaxel |
|
Phase 3 |
|
|
|
7 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
8 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
9 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Antiprotozoal Agents |
|
Phase 2, Phase 3 |
|
|
|
12 |
|
Antiparasitic Agents |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
14 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
15 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
16 |
|
Mitomycin |
Approved |
Phase 2 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
17 |
|
Pembrolizumab |
Approved |
Phase 1, Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
18 |
|
Antiemetics |
|
Phase 2 |
|
|
|
19 |
|
Immunoglobulins |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Antibodies, Monoclonal |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Antibodies |
|
Phase 1, Phase 2 |
|
|
|
22 |
|
Antineoplastic Agents, Immunological |
|
Phase 1, Phase 2 |
|
|
|
23 |
|
Immunologic Factors |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Vaccines |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Pancrelipase |
Approved, Investigational |
|
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
26 |
|
Proflavine |
Approved |
|
|
92-62-6 |
7099 |
Synonyms:
2,8-Diaminoacridine
3,6 Diamino acridine
3,6 Diaminoacridine
3,6-Acridinediamine
3,6-Diamino acridine
3,6-Diaminoacridine
Acridine, 3,6-diamino
|
DIAMINOACRIDINE
Hemisulfate, proflavine
Proflavin
Proflavina
Proflavine
Proflavine hemisulfate
Proflavinum
|
|
27 |
|
Liver Extracts |
|
|
|
|
|
28 |
|
Pancreatin |
|
|
|
|
|
29 |
|
Pharmaceutical Solutions |
|
|
|
|
|
30 |
|
Anti-Infective Agents, Local |
|
|
|
|
|
31 |
|
Fluorodeoxyglucose F18 |
|
|
|
|
|
32 |
|
Aluminum hydroxide, magnesium hydroxide, simethicone drug combination |
|
|
|
|
|
33 |
|
TEMPO |
|
|
|
|
|
Synonyms:
1,1,5,5-Tetramethylpentamethylene nitroxide
2,2,6,6-Tetramethyl-1-piperidinyloxy
2,2,6,6-Tetramethyl-1-piperidinyloxyl
2,2,6,6-Tetramethyl-4-piperidine-N-oxide
|
2,2,6,6-Tetramethylpiperidine-1-oxyl
2,2,6,6-Tetramethylpiperidinooxy radical
Oxoammonium tpo
|
|
Interventional clinical trials:
(show all 37)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial |
Unknown status |
NCT00726635 |
Phase 3 |
|
2 |
A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix |
Unknown status |
NCT00193739 |
Phase 3 |
NACT;Inj.Cisplatin |
3 |
A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago |
Completed |
NCT01937650 |
Phase 2, Phase 3 |
Radiotherapy plus metronidazole |
4 |
Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study |
Completed |
NCT05149248 |
Phase 2, Phase 3 |
|
5 |
Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA |
Completed |
NCT00191100 |
Phase 3 |
Gemcitabine;Cisplatin |
6 |
High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix |
Completed |
NCT00193830 |
Phase 3 |
|
7 |
Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial |
Completed |
NCT02765919 |
Phase 3 |
|
8 |
An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix |
Unknown status |
NCT02492503 |
Phase 1, Phase 2 |
Paclitaxel and carboplatin |
9 |
Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) |
Unknown status |
NCT02879214 |
Phase 2 |
|
10 |
A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease |
Unknown status |
NCT03101995 |
Phase 2 |
Gemcitabine |
11 |
Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression |
Completed |
NCT02309658 |
Phase 2 |
gemcitabine;cisplatin |
12 |
A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy. |
Recruiting |
NCT04652076 |
Phase 1, Phase 2 |
NP137;Pembrolizumab;Paclitaxel;Carboplatin |
13 |
A Safety Lead in Single Arm Phase II Study for Image Guided Ultrafractionated Radiation Therapy for Treatment of Metastatic Cervical Cancer |
Recruiting |
NCT05021237 |
Phase 2 |
|
14 |
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients |
Active, not recruiting |
NCT02865135 |
Phase 1, Phase 2 |
DPX-E7 vaccine |
15 |
A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) |
Withdrawn |
NCT03834571 |
Phase 2 |
Carboplatin;Cisplatin;Paclitaxel |
16 |
A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors |
Withdrawn |
NCT02312804 |
Phase 1 |
BGJ398;Carboplatin;Paclitaxel |
17 |
Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation |
Unknown status |
NCT01049100 |
|
|
18 |
A Nonrandomized, Non-double Blinded Prospective Cohort Study to Evaluate the Preventive Efficacy of Quadrivalent HPV6/11/16/18 Vaccine for the Persistent Infection of HPV16 Genotype or HPV18 Genotype in Japanese Women Aged 27-45 Years. |
Unknown status |
NCT04022148 |
|
|
19 |
The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus |
Unknown status |
NCT00154479 |
|
|
20 |
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) |
Unknown status |
NCT03133286 |
|
|
21 |
Algorithm for Cervix Carcinoma Screening in the Czech Republic Using the Detection of HPV DNA With Selective HPV 16/18 Genotype and Special CINtec Plus Cytological Colouring |
Completed |
NCT05578833 |
|
|
22 |
Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma |
Completed |
NCT00053261 |
|
|
23 |
Predicting Outcome in Cervix Carcinoma: a Prospective Study |
Completed |
NCT01825005 |
|
|
24 |
A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy |
Completed |
NCT01991808 |
|
|
25 |
Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study |
Completed |
NCT01759355 |
|
|
26 |
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix |
Completed |
NCT02206048 |
|
Proflavine |
27 |
A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix |
Completed |
NCT00193804 |
|
|
28 |
Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial |
Completed |
NCT00193791 |
|
|
29 |
Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cervical Cancer |
Completed |
NCT00193752 |
|
|
30 |
Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy |
Completed |
NCT04809727 |
|
|
31 |
High Intensity Interval Training (HIIT) on Stationary Bike With and Without Compression Stockings for Patients With Cancer-related Lymphedema in the Lower Limbs - a Feasibility Study |
Completed |
NCT03653819 |
|
|
32 |
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation |
Recruiting |
NCT04626466 |
|
|
33 |
The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology) |
Recruiting |
NCT03896958 |
|
|
34 |
Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling |
Recruiting |
NCT05179824 |
|
|
35 |
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
Recruiting |
NCT03452774 |
|
|
36 |
Minimally Invasive Therapy Versus Open Radical Hysterectomy (MITOR) for Management of Early Stage Cervical Cancer |
Not yet recruiting |
NCT04999696 |
|
|
37 |
Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy |
Terminated |
NCT01641484 |
|
|
|